Alnylam is leading the translation of RNA interference into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system. Alnylam’s commercial RNAi therapeutic products are ONPATTRO, approved in the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI, approved in the U.S and the EU.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Alnylam Pharmaceuticals news
28.04.2022
Alnylam Pharmaceuticals' GAAP loss for 3 months of 2022 was $240.341 million, up 20% from $200.291 million in the previous year. Revenue increased 20.1% to $213.259 million from $177.566 million a year earlier.
Source: 
investors.alnylam.com
investors.alnylam.com
10.02.2022
Alnylam Pharmaceuticals' GAAP loss for 2021 was $852.824 million, down 0.6% from $858.281 million in the previous year. Revenue increased 71.3% to $844.287 million from $492.853 million a year earlier.
Source: investors.alnylam.com
investors.alnylam.com
28.10.2021
Alnylam Pharmaceuticals' GAAP loss for 9M 2021 was $594.364 million, down 3.3% from $614.741 million in the previous year. Revenue increased 77.9% to $585.752 million from $329.291 million a year earlier.
Source: investors.alnylam.com
investors.alnylam.com
03.08.2021
Alnylam Pharmaceuticals' GAAP loss for 6 months of 2021 was $389.85 million, up 7.9% from $361.45 million in the previous year. Revenue increased 95.7% to $398.119 million from $203.438 million a year earlier.
Source: investors.alnylam.com
investors.alnylam.com
General information
| Company name | Alnylam Pharmaceuticals |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 300 THIRD STREET CAMBRIDGE MA 02142 (617) 551-8200 |
| Mailing address | 300 THIRD STREET CAMBRIDGE MA 02142 |
| Website | www.alnylam.com |
| Information disclosure | www.sec.gov |
English (US) 